-
EP3507286
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3507286
| EP3507286 - CRYSTALLINE HYDRATE OF THE COMPOUND (2S,3R)-ISOPROPYL 2-(((2-(1,5-DIMETHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-1-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-1H-BENZO[D]IMIDAZOL-5-YL)METHYL)AMINO)-3-HYDROXYBUTANOATE EDISYLATE [Right-click to bookmark this link] | Status | Grant of patent is intended Status updated on 04.01.2024 Database last updated on 24.08.2024 | |
| Former | Examination is in progress Status updated on 20.11.2023 | ||
| Former | Grant of patent is intended Status updated on 30.03.2023 | ||
| Former | Examination is in progress Status updated on 16.12.2019 | ||
| Former | Request for examination was made Status updated on 07.06.2019 | ||
| Former | The international publication has been made Status updated on 10.03.2018 | ||
| Former | unknown Status updated on 08.09.2017 | Most recent event Tooltip | 18.06.2024 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states GlaxoSmithKline Intellectual Property Development Limited 980 Great West Road Brentford Middlesex TW8 9GS / GB | [2019/28] | Inventor(s) | 01 /
HENLEY, Nicholas Paul GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY / GB | [2019/28] | Representative(s) | Ahern, Jenna Marie GlaxoSmithKline Global Patents, CN925.1 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [N/P] |
| Former [2019/28] | Fowler, Gavin James GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 17758877.9 | 31.08.2017 | [2019/28] | WO2017EP71867 | Priority number, date | GB20160014939 | 02.09.2016 Original published format: GB 201614939 | [2019/28] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018041946 | Date: | 08.03.2018 | Language: | EN | [2018/10] | Type: | A1 Application with search report | No.: | EP3507286 | Date: | 10.07.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.03.2018 takes the place of the publication of the European patent application. | [2019/28] | Search report(s) | International search report - published on: | EP | 08.03.2018 | Classification | IPC: | C07D405/14, A61P19/02, A61K31/4427 | [2019/28] | CPC: |
C07D405/14 (EP,KR,US);
A61K31/4427 (KR);
A61P19/02 (EP,KR,US);
C07B2200/13 (KR,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/28] | Extension states | BA | 28.03.2019 | ME | 28.03.2019 | Title | German: | KRISTALLINES HYDRAT DER VERBINDUNG (2S,3R)-ISOPROPYL-2-(((2-(1,5-DIMETHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-1-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-1H-BENZO[D]IMIDAZOL-5-YL)METHYL)AMINO)-3-HYDROXYBUTANOAT-EDISYLAT | [2019/28] | English: | CRYSTALLINE HYDRATE OF THE COMPOUND (2S,3R)-ISOPROPYL 2-(((2-(1,5-DIMETHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-1-((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)-1H-BENZO[D]IMIDAZOL-5-YL)METHYL)AMINO)-3-HYDROXYBUTANOATE EDISYLATE | [2019/28] | French: | HYDRATE CRISTALLIN DU COMPOSÉ (2S,3R)-ISOPROPYL 2-(((2-(1,5-DIMÉTHYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-1-((TÉTRAHYDRO-2H-PYRAN-4-YL)MÉTHYL)-1H-BENZO[D]IMIDAZOL-5-YL)MÉTHYL)AMINO)-3-HYDROXYBUTANOATE ÉDISYLATE | [2019/28] | Entry into regional phase | 28.03.2019 | National basic fee paid | 28.03.2019 | Designation fee(s) paid | 28.03.2019 | Examination fee paid | Examination procedure | 28.03.2019 | Amendment by applicant (claims and/or description) | 28.03.2019 | Examination requested [2019/28] | 28.03.2019 | Date on which the examining division has become responsible | 19.12.2019 | Despatch of a communication from the examining division (Time limit: M06) | 18.09.2020 | Reply to a communication from the examining division | 08.02.2021 | Despatch of a communication from the examining division (Time limit: M04) | 12.05.2021 | Reply to a communication from the examining division | 29.07.2021 | Despatch of a communication from the examining division (Time limit: M06) | 31.01.2022 | Reply to a communication from the examining division | 31.03.2023 | Communication of intention to grant the patent | 10.08.2023 | Fee for grant paid | 10.08.2023 | Fee for publishing/printing paid | 17.11.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 05.01.2024 | Communication of intention to grant the patent | 17.06.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 17.11.2023 | Request for further processing filed | 17.11.2023 | Full payment received (date of receipt of payment) Request granted | 01.12.2023 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 18.09.2020 | Request for further processing filed | 18.09.2020 | Full payment received (date of receipt of payment) Request granted | 02.10.2020 | Decision despatched | Fees paid | Renewal fee | 08.08.2019 | Renewal fee patent year 03 | 17.08.2020 | Renewal fee patent year 04 | 18.08.2021 | Renewal fee patent year 05 | 19.08.2022 | Renewal fee patent year 06 | 22.08.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2015051208 (ENGELHARDT HARALD [AT], et al) [A] 1-18* Fromula (Ia1); paragraphs [0001] , [0 61]; claim -; compounds I-25 and I-27, IV-7 *; | [XDP]WO2016146738 (GLAXOSMITHKLINE IP DEV LTD [GB]) [XDP] 1-18 * pages 23-27; example 303 * | by applicant | GB2242134 | WO03061743 | WO2007012871 | WO2007068896 | WO2011054848 | WO2011054846 | - CHUNG et al., J Med. Chem, (20110000), vol. 54, pages 3827 - 3838 | - DAWSON M.A. et al., Nature, (20110000), vol. 478, no. 7370, pages 529 - 33 | - WYCE, A. et al., Oncotarget., (20130000), vol. 4, no. 12, pages 2419 - 29 | - NICODEME E. et al., Nature, (20100000), vol. 468, no. 7327, pages 1119 - 23 | - MELE D.A. et al., Journal of Experimental Medicine, (20130000), vol. 210, no. 11, pages 2181 - 90 | - ANAND P., Cell, (20130000), vol. 154, no. 3, pages 569 - 82 | - TANG X. et al., Molecular Pharmacology, (20130000), vol. 83, no. 1, pages 283 - 293 | WO2016EP55792 |